You can have confidence in your biosimilar medicines

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today welcomed the announcement by the Yukon Government that it is implementing a “switching” or transitioning policy to expand the use of biosimilar biologic medicines for its public drug programs.

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, welcomes the announcement by the Government of Newfoundland and Labrador that it is implementing a “switching” or transitioning policy to expand the use of biosimilar biologic medicines for its public drug program.

Biosimilars Canada is pleased to announce the unanimous election of Mr. Mike Woolcock, Senior Vice President of the Apobiologix division of Apotex, as Chair of the Biosimilars Canada Board. Mr. Mike Casia, President and Managing Director of Organon Canada, has been unanimously elected as Vice-Chair of the Biosimilars Canada Board.